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ABSTRACT 
 
Objective: Calcific aortic valve disease (CAVD) is a progressive condition that shares some 
common pathogenic features with atherosclerosis. Transforming growth factor (TGF)-β1 is a 
recognised mediator of atherosclerosis and is expressed in aortic valve lesions. TGF-β1 
stimulates glycosaminoglycan (GAG) elongation of proteoglycans that is associated with 
increased lipid binding. We investigated the presence of TGF-β1 and downstream signaling 
intermediates in diseased human aortic valves and the effects of activated TGF-β1 receptor 
signaling on aortic valve interstitial cell (VIC) proteoglycan synthesis and lipid binding as a 
possible mechanism for initiation of the early lesion of CAVD. 
Methods and Results: Diseased human aortic valve leaflets demonstrated strong 
immunohistochemical staining for TGF-β1 and phosphorylated Smad2/3. In primary porcine 
aortic VICs Western blots showed TGF-β1 stimulated phosphorylation in both the carboxy and 
linker regions of Smad2/3 which was inhibited by the TGF-β1 receptor inhibitor SB431542. Gel 
electrophoresis and size exclusion chromatography demonstrated that SB431542 decreased TGF-
β1-mediated [35S]-sulfate incorporation into proteoglycans in a dose-dependent manner. Further, 
in proteoglycans derived from TGF-β1 treated VICs, gel mobility shift assays demonstrated that 
inhibition of TGF-β1 receptor signaling resulted in decreased lipid binding.   
Conclusions: Classic TGF-β1 signaling is present in human aortic valves in vivo, and contributes 
to the modification of proteoglycans expressed by VICs in vitro. These findings suggest that 
TGF-β1 may promote increased LDL binding in the early phases of CAVD. 
 
KEYWORDS  heart valves, Smad, transforming growth factor-β, lipids, glycosaminoglycans 
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ABBREVIATIONS 
CAVD calcific aortic valve disease 
GAG glycosaminoglycan 
LDL low density lipoprotein 
pSmad2/3 phosphorylated Smad2/3 
TGF-β1 transforming growth factor 
VIC valve interstitial cell 
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Calcific aortic valve disease (CAVD), which includes aortic sclerosis and stenosis, is a 
progressive condition associated with substantial morbidity and mortality [1,2]. The 
prevalence of aortic sclerosis increases with age, 20% in patients 65-75 years and 48% in 
patients older than 85 years [3]. Advanced CAVD is the second most common indication for 
cardiac surgery in the Western world [4]. Originally considered a degenerative disease CAVD 
is now recognized as the result of active pathological processes.[5,6] There are indications 
that CAVD shares pathogenic features with atherosclerosis [7,5,8-10]. Risk factors including 
age, male gender, hypertension, hyperlipidemia and active inflammation have been associated 
with both CAVD and atherosclerosis [11,12,2,13,14] however the disease processes are not 
identical. Laboratory and clinical studies have suggested that the progression of aortic 
stenosis might be retarded by the use of statins [15-18] and ACE inhibitors [19-22]. However 
the results of controlled randomized intervention studies with statins in late-stage CAVD (i.e. 
aortic stenosis) have been negative [23-25]. With the unmet clinical need for effective CAVD 
treatments it is recognized that the pathological consequences of early aortic valve changes in 
CAVD need to be elucidated at a molecular level to identify suitable new targets and develop 
rational therapeutic interventions.[5,6,26].  
A hallmark of early CAVD is the structural and compositional change in the aortic valve 
extracellular matrix. Early valve thickening is characterized by disruption of the trilayer 
structure with disorganised collagen deposition in the fibrosa [27], accumulation of 
proteoglycans versican, biglycan and decorin [28,29], lipoproteins LDL, Lp(a), and ApoE as 
well as calcium [30] and inflammatory cell infiltrate [7]. Recently it has been highlighted that 
despite the abundance of proteoglycans and glycosaminoglycans in sclerotic and stenotic 
aortic valves their role in CAVD is almost completely unexplored [31]. Transforming growth 
factor (TGF)-β1 is a recognised mediator of atherosclerosis and is also expressed in aortic 
valve lesions [32]. However the role of TGF-β1 in the initiation and progression of CAVD is 
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not clear with context-dependent effects of TGF-β1 described with in vitro and in vivo models 
of CAVD. In atherosclerosis, TGF-β1 leads to the activation of proteoglycan synthesis in 
vascular smooth muscle cells and induces elongation of the glycosaminoglycan (GAG) chains 
[33,34]. Elongated GAG chains are capable of increased binding of lipid [34,35] and this 
interaction underlies the “response to retention” hypothesis of Williams and Tabas regarding 
the origin of atherosclerosis [36]. In this study we investigated TβR signaling in diseased 
human aortic valves and the effects of TGF-β1 on porcine aortic valve interstitial cell 
proteoglycan synthesis and lipid binding to determine whether the proteoglycans produced by 
aortic valve interstitial cells could have a role in the initiation of the early sclerotic stage of 
CAVD.  
 
Methods 
Immunohistochemical analysis 
 Valve leaflets were fixed in 4% paraformaldehyde in 0.1M phosphate buffer overnight 
prior to processing. Radial cross-sections from intact leaflets were cut from annulus to free 
edge, embedded in paraffin, and cryosectioned in 5 - 10 micron thick sections according to 
routine procedures. Immunohistochemistry was performed to evaluate distribution and 
expression of extracellular matrix components. Primary antibodies were to TGF-β1 (R&D 
Systems, 1:20), and phosphorylated Smad2/3 (Chemicon, 1:1000). A universal 
streptavidin/biotin (Vector Laboratories, Burlingame, CA) and diaminobenzidine detection 
system (DAKO, Denmark) was used for colorimetric detection. Negative controls for all 
markers were performed in the absence of primary antibodies. Sections were counterstained 
with hematoxylin and images recorded using a Zeiss microscope with a Zeiss Axiocam digital 
camera (Germany). A total of seven tricuspid aortic valves were studied. Stenotic valves 
(three female 74, 75 and 82 years and two male 62 and 76 years) were obtained at valve 
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replacement surgery and control valves (female 54 and male 73 years) were collected from 
hearts undergoing non-valve disease-related heart surgery as approved by the Alfred Hospital 
Ethics Committee (Prahran, Australia). 
Isolation of aortic valve interstitial cells 
 Aortic valve interstitial cells (VICs) were isolated from porcine aortic valves collected 
from three pig hearts according to previously published methods [37]. Briefly, valve leaflets 
were dissected from the aortic root and rinsed in sterile PBS. To assist with removal of 
endothelial cells, partial digestion of the leaflets was performed with collagenase type II (2 
mg/mL, Sigma-Aldrich, USA) in serum free DMEM (Invitrogen) for 20 minutes at 37oC in an 
incubated shaker. Leaflet surfaces were then wiped with sterile swabs, cut into 1 mm pieces 
and placed into collagenase type III (2 mg/mL in DMEM) for 2-3 hours at 37oC with shaking. 
The digest was strained through a 100 micron filter and cells were pelleted. Cells were then 
dispersed in fresh medium (DMEM containing 5 mmol/L glucose, 10% FBS, 1% antibiotics), 
and plated in 75 cm2 flasks. For experimentation, cells between passages one to four were 
used. Confluent cultures were serum-deprived by incubation in DMEM (5 mmol/L glucose, 
0.1% FBS) for 48 hours prior to treatment.  
Analysis of proteoglycans and glycosaminoglycans 
 Quiescent cells were treated in DMEM containing 5 mmol/L glucose, 0.1% FBS, 
0.1% DMSO with SB431542 (0-10 µmol/L) an inhibitor of ALK5 or SIS3 (0.1-3 µM) an 
inhibitor of Smad3 phosphorylation and exposed to [35S]sulfate (1.85 MBq/mL) or 
[3H]glucosamine (0.37 MBq/mL) under basal conditions or in the presence of TGF-β1 (0-5 
ng/mL) for 24 hours, unless otherwise stated. To synthesize xyloside-initiated GAG chains 
(an independent measure of GAG synthesis) treatment media was supplemented with methyl 
β-D-xylopyranoside (0.5 mmol/l, Sigma). Secreted proteoglycans were isolated and 
concentrated from the conditioned medium as described previously[34]. Radiolabel 
  Osman 
 
 7 
incorporation into proteoglycans was quantified using the CPC precipitation assay [38]. The 
sizes of the proteoglycans and GAG chains (cleaved chemically from the proteoglycan core 
proteins via a β-elimination reaction [39]) were analysed by gradient SDS-PAGE [38]. GAG 
chain lengths also were analysed by size exclusion chromatography as described previously 
[40] and the data standardised by calculation of Kav values. 
Western blotting 
 Total cell lysates from VIC cultures treated with TGF-β1 (2 ng/ml) and/or SB431542 
(3 µM) for 24 hours were resolved on 10% SDS-PAGE and transferred onto PVDF 
membranes. Membranes were blocked with 5% skim milk powder for one hour at room 
temperature. Membranes were probed with primary antibodies as listed overnight at 4oC and 
then incubated with species specific secondary HRP-IgG (1:5000, 1 hour, RT) followed by 
enhanced chemiluminescent detection of proteins (ECL, Amersham).  To assess protein 
loading the membrane was reprobed with anti-smooth muscle α-actin mouse monoclonal 
antibody (Dako, 1:1000, 1 hour, RT) or anti-GAPDH rabbit monoclonal antibody (Cell 
Signaling, USA) followed by incubation with anti-mouse IgG (1:5000, 1 hour, RT) or anti-
rabbit IgG (1:5000, 1 hour, RT) respectively. Antibodies to phosphorylated-Smad2,-Smad2C 
and –Smad2L were obtained from Cell Signaling (USA). 
Gel mobility shift assay 
 Quiescent VICs were treated with SB431542 (3 µmol/L) and TGF-β1 (2 ng/mL) for 
24 hours in the presence of [35S]-Met/Cys (1.85 MBq/mL) to radiolabel the proteoglycan core 
proteins. Increasing concentrations of LDL (0-0.5 mg/mL) purified by ultracentrifugation 
from human blood[41] were incubated with equal counts (1250 cpm) of proteoglycans. Bound 
and free proteoglycans were separated on flat bed agarose gels as described previously.[40] 
Dried agarose gels were exposed to phosphorscreens and calculation of bound proteoglycans 
was performed using MacBas software (v1, Fuji Photo Film Co., Japan). 
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Data analyses 
 Western blots were in triplicate and density analysis performed using Image Lab 
(BioRad). All data for proteoglycan experiments were collected in triplicate from at least two 
separate experiments. Data were calculated as means and standard errors and were compared 
using one-way ANOVA, two-way ANOVA, or Student’s t-tests as indicated, with 
significance accepted at p<0.05. 
 
RESULTS 
Expression of TGF-β1 and phosphorylated Smad2/3 in human calcified and non-
calcified aortic valve leaflets 
 Immunohistochemical staining was used to determine whether the TβR - Smad2/3 
pathway is activated in CAVD. Human calcified and normal non-calcified aortic valve leaflets 
were examined for expression of the TβR ligand, TGF-β1 and downstream signaling 
intermediate phosphorylated Smad2/3 (pSmad2/3) and representative sections are shown 
(Figure 1). In all of the diseased valves TGF-β1 staining was seen throughout the markedly 
thickened layers and the strongest expression was found in close proximity to calcific nodules 
(Figure 1B). Examination of the stained valves at higher magnification showed diffuse strong 
intracellular and extracellular staining in the spongiosa region for TGF-β1 (data not shown). 
The calcific remnants were stained dark purple by haematoxylin. A similar distribution of 
pSmad2/3 staining was visible in CAVD valves and prominent nuclear staining was also 
evident (Figure 1D). In contrast all of the non-diseased valve leaflets had much lower levels 
of TGF-β1 (Figure 1A) and less intense pSmad2/3 staining with less prominent nuclear 
staining (Figure 1C). Thus in the calcific stages of CAVD we observed staining that indicates 
an activated TβR - Smad2/3 pathway in the valves. 
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TGF-β1 mediates phosphorylation of Smad2/3 in aortic valve interstitial cells 
 As it remains technically difficult to demonstrate the activity of the TβR - Smad2/3 
pathway in situ at the initiation stages of CAVD due to the lack of availability of suitable 
valves we instead utilised isolated porcine aortic valve interstitial cells (VICs). Western blots 
demonstrated VICs expressed smooth muscle α-actin to the same extent under basal and 
TGFβ-stimulated conditions (Figure 2A) demonstrating an activated myofibroblast-like 
phenotype that is associated with aortic valve pathology and remodelling [42,43]. After 4 
hours stimulation with TGF-β1 (Figure 2A) VICs showed a nine-fold increase in serine 
phosphorylation of Smad2/3 at the carboxy terminus (pSmad2/3C) above basal and a five-fold 
increase in serine phosphorylation of the linker region of Smad2 (pSmad2L). Inhibition of 
TβR1 serine kinase activity with its highly specific inhibitor SB431542 (3 µM) reduced 
phosphorylation of Smad2/3 back to basal levels (Figure 2A). Total Smad2/3 expression 
levels remained constant under all treatments. Clearly in VICs TβR1 can be activated to 
phosphorylate multiple serine residues in different regions of Smad2/3. 
 We next performed an early time-course study of TβR1-mediated Smad2/3 
phosphorylation. VICs were treated with TGF-β1 for 5, 15, 30, 60 and 120 minutes and 
Western blots of whole cell lysates probed for pSmad2/3C and pSmad2L (Figure 2B). 
Carboxy terminal phosphorylation was significantly above basal within 15 minutes (p<0.001) 
and was sustained up to 120 minutes. Linker region phosphorylation was slower peaking at 60 
minutes. Smad2/3 linker region phosphorylation in some contexts is known to be a 
consequence of TβR1-mediated activation of the MAP kinase Erk1/2. The blots were 
reprobed to look for activation of Erk1/2 in VICs and we found a two-fold increase in pErk1/2 
within 15 - 30 minutes of TGF-β1 stimulation (Figure 2B) however this did not reach 
statistical significance. 
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 To clarify the extent of MAP kinase involvement in Smad2/3 linker phosphorylation 
we pre-incubated VICs with each of the specific MAP kinase inhibitors UO126 (MEK1/2 
inhibitor that blocks Erk1/2), SP600125 (Jnk inhibitor) and SB202190 (p38 inhibitor) and 
then stimulated with TGF-β1 for 4 hours to ensure sustained Smad2/3 activation (Figure 2C). 
None of the MAP kinase inhibitors blocked carboxy or linker region phosphorylation of 
Smad2/3 significantly while TβR1 inhibitor SB431542 completely blocked phosphorylation 
as expected. These results suggest that in VICs at 4h post- TGF-β1 treatment Smad2/3 linker 
phosphorylation is not dependent on MAP kinase activation. However further studies would 
be useful to clarify the role of MAP kinases in Smad2/3 linker phosphorylation at 30 -60 
minutes following TβR1 activation.  
Antagonism of TβR1 inhibits TGF-β1 mediated proteoglycan synthesis and GAG 
elongation 
 In previous studies we and others have shown that activation of the TβR - Smad2/3 
pathway increases proteoglycan synthesis in vascular smooth muscle cells and induces 
elongation of the glycosaminoglycan (GAG) chains and consequently greater lipid binding 
capacity[33,34]. From our findings of TβR - Smad2/3 pathway activation in VICs we 
hypothesized that a similar upregulation of proteoglycan synthesis and GAG elongation may 
occur in these cells and potentially contribute to the thickening of valve cusps in CAVD.  
 To evaluate the involvement of the classic TGF-β1-mediated cell signalling pathway 
in proteoglycan synthesis VICs were stimulated with TGF-β1 (2 ng/mL) in the presence of 
SB431542 (0 - 10 µmol/L). SB431542 decreased TGF-β1-mediated [35S]-sulfate 
incorporation into proteoglycans in a dose-dependent manner, with data normalised to 0% and 
100% inhibition at 0 µmol/L and 0.03-10 µmol/L SB431542, respectively (Figure 3A).  The 
IC50 for SB431542 was approximately 0.7 µmol/L. At 3 µmol/L SB431542, TGF-β1-
mediated [35S]-sulfate incorporation was inhibited by 77%, with no observed decrease in cell 
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number. This concentration of SB431542 was chosen for subsequent experiments. SB431542 
treatment resulted in a dose-dependent increase in electrophoretic mobility of complete 
proteoglycans compared to TGF-β1 treatment alone, indicating a decrease in proteoglycan 
size (Figure 3B). An alternate radiolabel, [3H]-glucosamine was employed to confirm these 
findings. Under basal conditions, SB431542 decreased [3H]-glucosamine incorporation by 
approximately 20%, (Figure 3C). TGF-β1 stimulated an 87% increase in [3H]-glucosamine 
incorporation, p<0.01, which was 100% inhibited in the presence of SB431542, p<0.01 
(Figure 3C). TGF-β1 stimulated a 12% increase in proteoglycan core protein synthesis 
compared to control (p<0.01), which was decreased by 19% in the presence of SB431542 
(data not shown). To determine whether both Smad2 and Smad3 are involved in TGF-β1-
mediated proteoglycan synthesis we employed SIS3, a compound which inhibits TGF-β1-
mediated phosphorylation of Smad3. In VICs TGF-β1 stimulated a 70% increase in [35S]-
sulfate incorporation into proteoglycans that was not significantly affected by the presence of 
0.1-3 µM SIS3 (Figure 3D). These data indicate that in this context phosphorylation of Smad2 
rather than Smad3 mediates TGF-β1-induced proteoglycan synthesis. 
 To analyse whether the observed proteoglycan size changes were due to changes in 
GAG chain length, size exclusion chromatography was employed. Initially, GAG chains were 
chemically cleaved from proteoglycan core proteins via a β-elimination reaction and both 
complete proteoglycans and chemically cleaved GAG chains were separated by SDS-PAGE 
(Figure 4A). Under basal conditions, SB431542 treatment of VICs had negligible effect on 
the electrophoretic mobilities of either complete proteoglycans or cleaved GAG chains 
compared to control (Figure 4A). TGF-β1 treatment resulted in a decrease in electrophoretic 
mobility of both complete proteoglycans and cleaved GAG chains relative to control, which 
was attenuated in both cases in the presence of SB431542 (Figure 4A). Analysis of cleaved 
GAG chain length by size exclusion chromatography confirmed that the increase in GAG size 
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demonstrated by SDS-PAGE was due to increased chain length. One representative analysis 
is shown in Figure 4B with the vertical line indicating mean Kav of control and the combined 
results are shown in Table 1. Under basal conditions, cleaved GAG chains derived from 
SB431542 treated VICs had a mean Kav of 0.42±0.01 compared to 0.41±0.01 for control 
(Table 1). In the presence of TGF-β1, SB431542 treatment resulted in GAG chains with a 
mean Kav of 0.41±0.01 compared to 0.36±0.01 for TGF-β1 treatment alone, p<0.02 (Table 1) 
indicating a stimulation of GAG elongation in the presence of TGF-β1 that was inhibited by 
SB431542. 
 Synthesis of GAG chains on a xyloside primer is a technique that allows evaluation of 
GAG synthesis independent of the proteoglycan core protein and was used to confirm TGF-
β1-mediated effects on GAG chains. VICs were treated with SB431542 under basal 
conditions and in the presence of TGF-β1 in culture media supplemented with β-xyloside. 
TGF-β1 treatment increased [35S]-sulfate incorporation by 136%, p<0.01 (Figure 5A). 
SB431542 treatment had little effect under basal conditions but inhibited the TGF-β1-
mediated increase in [35S]-sulfate incorporation by 88%, p<0.01 (Figure 5A). Xyloside-
initiated GAG chains were separated by SDS-PAGE (Figure 4B). TGF-β1 treatment resulted 
in xyloside initiated GAG chains with decreased electrophoretic mobility, indicative of an 
increase in GAG size (Figure 5B). SB431542 inhibited this TGF-β1-mediated change in 
electrophoretic mobility. By size exclusion chromatography, TGF-β1 treatment decreased the 
mean Kav of xyloside-initiated GAG chains from 0.53±0.01 for control to 0.48±0.01, p<0.02, 
(Table 1, Figure 5C) indicating an increase in GAG chain size. SB431542 treatment under 
basal conditions and in the presence of TGF-β1 resulted in mean Kav values of 0.52±0.01 and 
0.54±0.01 (p<0.05 vs TGF-β1), respectively (Table 1), indicating that SB431542 inhibited 
TGF-β1-mediated increases in xyloside-initiated GAG elongation. 
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TβR1 inhibition decreases VIC proteoglycan/low density lipoprotein binding 
 To assess the role of TβR1 in the LDL binding to secreted proteoglycans from TGF-
β1-stimulated VICs, gel mobility shift assays were used (Figure 6). The migration of 
proteoglycans, metabolically radiolabelled with [35S]-Met/Cys, through agarose gel is reduced 
in the presence of increasing amounts of bound LDL. Proteoglycans from cells treated with 
SB431542 + TGF-β1 had decreased LDL binding compared to TGF-β1 treatment alone, 
p<0.001 (Figure 6A). The half maximal saturation value for proteoglycans from SB431542 
treated cells in the presence of TGF-β1 was approximately four-fold higher at 0.13 mg/mL 
compared to 0.03 mg/mL for TGF-β1 treatment alone, indicating a substantial decrease in 
LDL binding affinity with SB431542 treatment. The LDL binding capacity of proteoglycans 
from SB431542 treated cells in the presence of TGF-β1 treated cells was also decreased 
compared to proteoglycans from TGF-β1 treated cells (Figure 6A). Thus inhibition of TβR1-
mediated changes in VIC proteoglycans is sufficient to reduce the ability of the proteoglycans 
to bind LDL. 
 
DISCUSSION 
 The pathological and actively regulated disease processes of CAVD have been well 
recognised recently and understanding basic valve biology and signaling pathways of VICs is 
acknowledged as a high priority for progress in CAVD research [44]. Diseased valves have 
been shown previously to express the pleiotropic growth factor, TGF-β1[32,30,45] and a 
mouse model of CAVD has demonstrated elevated levels of phosphorylated Smad 
transcription factors in aortic valves [46]. This study demonstrates that in human aortic valve 
lesions expression of both TGFβ1 and phosphorylated Smad2/3 are elevated throughout the 
thickened valve leaflets. Because TGF-β1 may be present in tissues in both active and latent 
forms, demonstrating the presence of TGF-β1 cannot determine whether the molecule is 
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biologically active. However, canonical signaling by active TGF-β1 involves phosphorylation 
of Smad2/3 by TβR1 and subsequent translocation of pSmad2/3 to the nucleus. Thus, the 
demonstration that, in regions with immunostaining for TGF-β1, positive staining was also 
detected for both cytoplasmic and nuclear localization of pSmad2/3 provides supportive 
evidence of active TGF-β1 signalling in human aortic valve lesions. TGF-β1 and pSmad2/3 
colocalization is also reported to occur in early lesions of the fibrosa in aortic valve leaflets 
from hypercholesterolemic pigs [47]. Significantly elevated levels of pSmad2/3 are also 
observed in mouse models of early stage CAVD [46] and after lipid lowering treatment in late 
stage CAVD mouse models [48] and underlines the key role Smad2/3 in CAVD processes. 
 We investigated the signaling pathways through which TGF-β1 mediates its effects in 
VICs and demonstrated the involvement of the canonical Smad phosphorylation pathway. In 
porcine VICs TGF-β1 stimulated a significant increase in the level of both pSmad2/3C and 
pSmad2/3L. This specific response was blocked by SB431542, an inhibitor of the kinase 
activity of TβR1, for which both Smad2 and 3 are targets. Phosphorylation of Smad2/3 
carboxy terminus was immediate and rapid, within 5 min, while linker region phosphorylation 
was elevated significantly after 30 minutes of TGF-β1 stimulation (Figure 2). A similar 
differential in regional Smad2/3 phosphorylation is also seen in vascular smooth muscle cells 
[49]. Blocking pSmad2/3 phosphorylation inhibited proteoglycan GAG elongation however 
further studies are necessary to determine whether these downstream processes have a 
requirement for phosphorylation of both carboxy terminal and linker regions. Our results 
indicate that at 4h after TGF-β1 stimulation the linker phosphorylation is not conditional on 
MAP kinase activity. Further investigations are necessary to determine if MAP kinases are 
important immediately following TGF-β1 stimulation or whether alternate linker region 
phosphorylation kinases possibly cyclin-dependent kinase, glycogen synthase 3-β, calcium-
calmodulin-dependent protein kinase II or G protein-coupled receptor kinase-2 are involved. 
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Our findings correlate with recent reports of activated Smad2/3 signaling with TGF-β1 treated 
porcine VICs grown in Wnt3A-conditioned media demonstrating induction of pSmad2/3 
nuclear translocation [47]. The phosphorylation of Smad2/3 in aortic valves appears cell and 
context dependent since pSmad2 levels are not elevated in human aortic valve endothelium 
both in non-calcified and calcified valves [50]. 
 Recently it was highlighted that despite an abundance of proteglycans and GAGs in 
valves in CAVD the role of proteoglycans and GAGs has not been investigated [31]. Our 
study demonstrates that in porcine VICs TGF-β1 weakly induces proteoglycan core protein 
synthesis, and strongly stimulates proteoglycan GAG chain elongation. In addition we have 
clearly demonstrated that this is mediated by the classical TGF-β1 signaling pathway and by 
application of a pharmacological approach using SIS3 showed that Smad3 was not involved 
in proteoglycan synthesis, thereby demonstrating that the pathway specifically involves 
phosphorylation of Smad2. Previous in vitro studies using smooth muscle cells (SMCs) have 
demonstrated that TGF-β1 stimulates elongation of GAG chains on SMC-secreted 
proteoglycans [33], specifically on the chondroitin sulfate (CS) /dermatan sulfate (DS) 
proteoglycans, biglycan and decorin [33] and that these TGF-β1-induced changes in SMC-
produced proteoglycans mediates increased lipoprotein binding [34]. In the present study we 
show that TGF-β1 has similar effects on proteoglycans produced by aortic VICs. In VICs, 
TGF-β1 stimulated GAG chain elongation on CS/ DS proteoglycans, as well as elongation of 
the GAGs initiated on xyloside. Moreover proteoglycans synthesized in response to TGF-β1 
demonstrate enhanced LDL binding, an effect that is blunted by inhibition of classical TGF-
β1 signalling via Smad2. This finding demonstrates that TGF-β1 is acting on proteoglycans 
primarily at the level of the GAG synthesizing machinery in the Golgi apparatus, an effect 
that is independent of the presence of core proteins. TGF-β1 also appears to stimulate a small 
increase in total proteoglycan core proteins by aortic VICs; we speculate that this is most 
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likely an increase in biglycan and/or decorin. Although in this study we did not formally 
evaluate which individual core proteins were increased because the apparent effect on core 
protein synthesis was small and because our major interest was in the more robust effect on 
GAGs and their binding to LDL. Specific proteoglycan identification may be useful 
considering the impact of extracellular matrix components on myofibroblast differentiation 
and behaviour in CAVD [51]. Biglycan and decorin are observed in early calcific nodule 
formation in human calcified aortic valves [29] and in late-stage CAVD there is increased 
accumulation of biglycan and with it a co-localization of oxidised-LDL, phospholipid transfer 
protein and Apo A1 [52]. By implicating biglycan and TGF-β1 influencing proteoglycan-
mediated retention of lipoproteins within CAVD lesions, these findings suggest that inhibition 
of TGF-β1 and/or manipulation of proteoglycan/lipoprotein interactions may represent novel 
therapeutic targets in CAVD.  
Our observation of increased lipid binding to proteoglycans synthesized by TGF-β1-
stimulated VICs raises the question of the validity of using lipid lowering drugs as a 
preventative measure in the early stages of aortic valve disease. To date the role of statin 
treatment to improve clinical outcome and reduce aortic stenosis progression is contradictory 
with beneficial effects supported only by observational studies and a lack of effect in the 
prevention of cardiovascular events or reduction of disease progression when given at a late 
stage of the disease [53]. Our findings would strongly support the hypothesis of the authors 
that the maximal efficacy of statins may be achieved at early stages of aortic stenosis when 
lipid binding to agonist induced hyperelongated glycosaminoglycan chains of proteoglycans 
synthesized by valve interstitial cells would be an active process during the thickening phase 
of the valve response. At the later calcific stages the extent of proteoglycan synthesis and 
hence lipid binding may well be reduced and overwhelmed by calcification and other 
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remodelling processes with the consequence that lipid lowering statin treatment would be less 
effective. 
 
 In conclusion, our data confirm that TGF-β1 is present in diseased human aortic 
valves, extends this observation to demonstrate the presence of important components of the 
canonical TGF-β1 signalling pathway in these same valves, and elucidates how stimulation of 
specific TGF-β1 signaling pathways affects proteoglycan synthesis and lipoprotein binding in 
cultured porcine VICs. Together, these findings provide strong support to the proposal that 
CAVD is a complex, mechanism based disease that shares some similar pathogenic features 
with atherosclerosis. Tentative evidence is provided that lipid trapping by modified GAG 
chains on proteoglycans may also represent an early step in CAVD, as has been 
hypothesized[54] and strongly implicated by recent data[55] for atherosclerosis. Although we 
have demonstrated that the canonical Smad phosphorylation pathway is present in diseased 
human aortic valves and cultured porcine VICs, studies of TGF-β1 signaling pathways in 
emerging animal models of CAVD would be of great interest. Moreover, TGF-β1 is critically 
involved in the immune system, most likely through Smad-dependent pathways.  Thus, 
notwithstanding the involvement of TGF-β1 in CAVD, blocking those pathways may not be 
an option for treating CAVD and atherosclerosis. However, recent evidence has shown that 
TGF-β1 signalling pathways are much more complex and can involve tyrosine and 
serine/threonine phosphorylation and activation of MAP kinases , particularly ERK and p38 
[56-58]. This investigation demonstrated a small but not statistically significant level of MAP 
kinase activity in VICs associated with TGFβ1-mediated Smad phosphorylation however this 
may reflect the 4 hour time point studied. p38 MAP kinase is activated by angiotensin II 
within 15 mins in VICs [59] and ERK1/2 is phosphorylated in calcifying VIC cultures but to a 
lesser extent in the absence of calcification [60]. This suggests that MAP kinase activity can 
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be induced at different stages of VIC activation. Taken together these observations raise a 
potential role for MAP kinase phosphorylation of Smads particularly in the Smad linker 
region. This might extend to an involvement of MAP kinase in the reported requirement of 
TGFβ1-induced pSmad2/3 and Wnt3A-induced β-catenin nuclear translocation in VIC 
myoblast differentiation [47]. In addition to Smad, Erk1/2 and p38 MAP kinases are involved 
in the regulation of GAG synthesis in vascular smooth muscle cells.[58,49]. Therefore, further 
investigations may provide an opportunity to discover Smad-independent TGF-β1 mediated 
signaling pathways that are associated with diseases processes and not immune functions, and 
that may well serve as more therapeutically useful targets for CAVD prevention and provides 
further strong impetus for studying the potential positive and/or negative effects of inhibiting 
these pathways in animal models of CAVD. Alternatively, strategies that avoid interference 
with TGF-β1 signaling by directly targeting proteoglycan/lipoprotein interactions may also 
represent useful therapeutic goals in CAVD. 
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FIGURE LEGENDS 
Figure 1. Expression of TGF-β and phosphorylated Smad2/3 is increased in CAVD. 
Immunohistochemistry on paraformaldehyde-fixed, paraffin-embedded human aortic valve 
leaflets, non-diseased (Normal) or late-stage CAVD (CAVD), was performed using 
antibodies against TGF-β (A and B) and phosphorylated Smad2/3 (C and D). Arrows indicate 
nuclear staining. Scale bars 100 µm. 
Figure 2 TGF-β activates carboxy and linker region phosphorylation of Smad2/3 in 
VICs. (A) Cells were pre-treated with medium (-) or the TβR1 inhibitor SB431542 (SB, 3 
µM) for 30 min prior to the addition of TGF-β (2 ng/ml) for 4h. Western blots of whole cell 
lysates were probed for carboxy phosphorylated Smad2/3 (pSmad2/3C) or linker region 
phosphorylated Smad2/3 (pSmad2/3L) and reprobed for total Smad2 and smooth muscle α-
actin. Density analysis of phospho-blots is plotted in the adjacent histogram. (B) Time-course 
of TGF-β-mediated Smad2/3 phosphorylation. Cells were treated with TGF-β (0 – 120 min) 
and Western blots of whole cell lysates probed for pSmad2/3C, pSmad2/3L and 
phosphorylated Erk1/2 (pErk1/2). (C) MAP kinase inhibition does not block Smad2/3 
phosphorylation in VICs. Cells were pre-treated with either medium (-), Erk1/2 blocker 
U0126 (UO, 3 µM), p38 inhibitor SB202190 (SB*, 3 µM), Jnk inhibitor SP600125 (SP, 1 
µM) or TβR1 inhibitor SB431542 (SB, 3 µM) for 30 min prior to the addition of TGF-β (2 
ng/ml) for 4h. Western blots of whole cell lysates were probed for pSmad2/3C, pSmad2/3L 
and GAPDH as a loading control. ### P<0.001 versus control, *** P<0.001 versus TGF and 
** P<0.01 versus TGF using a 1-way ANOVA. 
Figure 3. TβR1 mediates glycosaminoglycan elongation of VIC secreted proteoglycans 
(A) Inhibition of TβR1 by SB431542 dose-dependently decreases TGF-β mediated [35S]-
sulfate incorporation into proteoglycans secreted by VICs. Data was normalised to 0% and 
100% inhibition at 0 µM and 10 µM SB431542, respectively. Normalised data are shown as 
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mean ± SEM. (B). SB431542 treatment (0 – 10 µM) resulted in a concentration dependent 
increase in electrophoretic mobility of secreted proteoglycans compared to TGF-β (2 ng/ml) 
treatment alone (-), indicating a decrease in proteoglycan size. A representative gradient SDS-
PAGE (4-13%) is shown, the dotted line indicates estimated mid-line of biglycan band size. 
(C) Confirmation of TGF-β and SB431542 effects seen in (A) using alternate radiolabel [3H]-
glucosamine. Normalised data in each case are shown as mean ± SEM from at least two 
experiments in triplicate, **p<0.01 vs control and ##p<0.01 vs TGF-β using a 1-way 
ANOVA. (D) Specific inhibition of Smad3 phosphorylation using chemical inhibitor SIS3 (0- 
3 µM) does not block TGF-β mediated [35S]-sulfate incorporation into proteoglycans secreted 
by VICs.  
Figure 4. Size analysis of proteoglycans produced in VICs treated with TGF-β. (A) VICs 
were pre-treated with medium (-) or SB431542 (SB, 3 µM) for 30 min prior to the addition of 
TGF-β (2 ng/ml) for 24h in the presence of [35S]-sulfate to metabolically label proteoglycans. 
Secreted proteoglycans were isolated and purified by Sepharose anion exchange 
chromatography and subjected to SDS-PAGE (Complete PGs). Replicate samples were 
treated with sodium cyanoborohydride and alkali to cleave the GAG chains from the 
proteoglycan core protein. Free GAG chains were also analysed by SDS-PAGE (Cleaved 
GAG chains). A representative gradient gel (4-20%) is shown. The dotted line indicates 
estimated mid-line of biglycan band size for complete PGs and mid-line of cleaved GAG 
chain sizes. (B) Size exclusion chromatography (Sepharose CL-6B) of radiolabeled cleaved 
GAG chains isolated from secreted proteoglycans from treatments given in (A) medium 
(Con), SB431542 (SB), TGF-β (TGF), SB431542 and TGF-β (SB + TGF). Vertical dotted 
line indicates the calculated apparent Kav of control GAG chains. Three measurements were 
performed from three separate experiments with a representative shown. Note that TGF-β 
shifts the peak to the left, indicating larger size. 
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Figure 5. TGF-β increases the size of GAG chains initiated on xyloside by VICs. 
(A) TGF-β increased [35S]-sulfate incorporation into xyloside-GAGs and inhibition of TβR1. 
VICs were pretreated with medium (-) or SB431542 (SB 3 µM) for 30 min followed by TGF-
β (2 ng/ml) for 24h in the presence of [35S]-sulfate and β-xyloside (0.5 mM). Data show mean 
± SEM from two experiments in triplicate, **p<0.01 vs control and ##p<0.01 vs TGF-β using 
a 1-way ANOVA. (B) Xyloside-GAGs from above listed treatments were purified on DEAE-
Sepharose ion-exchange columns and then run on gradient SDS-PAGE gels (4 – 20%). A 
representative gel from three separate experiments is shown and the dotted line indicates 
estimated mid-line of xyloside-GAGs size. (C) Size exclusion chromatography (Sepharose 
CL-6B) of radiolabeled xyloside-GAG chains isolated from VICs. Treatments as given above 
medium (Con), SB431542 (SB), TGF-β (TGF), SB431542 and TGF-β (SB + TGF). Vertical 
dotted line indicates the calculated apparent Kav of control GAG chains. Three measurements 
were performed from three separate experiments with a representative shown. Note that TGF-
β shifts the peak to the left, indicating larger size. 
Figure 6. Inhibition of TβR1 reduces LDL binding to proteoglycans produced by TGF-
β-treated VICs Gel mobility shift assay for the analysis of LDL binding to proteoglycans (A 
and B) VICs were treated with medium (Control), TGF-β (2 ng/ml), TGF-β + SB431542 
(TGF-β+ SB) for 24h and proteoglycan core proteins were labelled with [35S]-Met/Cys (50 
µCi/ml). Equal counts of core protein-radiolabeled proteoglycans were combined with 
increasing concentrations of LDL and separated using the gel shift mobility assay. Three 
separate experiments were performed with data shown as mean ± SEM. ***p<0.001 using a 
2-way interaction ANOVA comparing the two data sets. Earlier experiments using 
proteoglycans isolated from vascular smooth muscle cells showed the effect of SB431542 
treatment alone on LDL binding is negligible (unpublished data). 
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Table 1.  Mean Kav values for GAG chains measured by size exclusion chromatography  
  
Control 
 
SB 
 
TGF-β 
 
SB + TGF-β 
Cleaved chains 
Kav 
 
    0.41±0.01 
 
    0.42±0.01 
 
    0.36±0.01# 
 
    0.41±0.01* 
Xyloside GAGs 
Kav 
 
    0.53±0.01 
 
    0.52±0.01 
 
    0.48±0.01θ 
 
    0.54±0.01κ 
SB SB154132, Kav values are expressed as mean ± SEM from three separate size exclusion 
experiments, #p<0.05 vs control, *p<0.02 vs TGF-β, θp<0.02 vs control, κp<0.05 vs TGF-β 
using a paired Student’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
